Form 4: Lucira Health, Inc. (LHDX), Kashmolah Ghazi, transaction 09/30/2021

Summary

Ghazi Kashmolah, whose officer title at Lucira Health, Inc. [ LHDX ] is printed "Ex. VP &Chief Quality Officer", reports a grant of 197,240 Restricted Stock Units on 09/30/2021, entered at $ 0.00 and payable solely in common stock of the issuer. The units vest over four years from a vesting start date of August 16, 2021: 25% on the first anniversary, then 12 equal quarterly installments. After the grant 197,240 shares are owned directly. Signed by /s/ Dan George, Attorney-in-Fact for Ghazi Kashmolah, 10/01/2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Kashmolah Ghazi (Last) (First) (Middle) C/O LUCIRA HEALTH, INC. 1412 62ND STREET (Street) EMERYVILLE CA 94608 (City) (State) (Zip) | Kashmolah Ghazi | (Last) | (First) | (Middle) | C/O LUCIRA HEALTH, INC. | 1412 62ND STREET | EMERYVILLE | CA | 94608 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Lucira Health, Inc. [ LHDX ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Ex. VP &Chief Quality Officer | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | Ex. VP &Chief Quality Officer
3. Date of Earliest Transaction
 (Month/Day/Year) 09/30/2021
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock | 09/30/2021 | A | 197,240 (1) | A | $ 0.00 | 197,240 | D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Explanation of Responses:
1. Represents grant of Restricted Stock Units (the "RSUs") payable solely in common stock of the Issuer that vest over a four-year period commencing on August 16, 2021 ("vesting start date"), with 25% of the shares subject to the RSUs vesting on the first anniversary of the vesting start date and the remainder of the shares subject to the RSUs vesting in 12 equal quarterly installments thereafter.
Remarks:
/s/ Dan George, Attorney-in-Fact for Ghazi Kashmolah | 10/01/2021
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_LHDX_4_filed2021-10-01_0001209191-21-058567.xml

Size

15,360 bytes

SHA-256

61b99941399679df090150a56ba54e1a1d4e3c37d257702f1cdc119af46bd972

Our copy

SEC_LHDX_4_filed2021-10-01_0001209191-21-058567.xml

Original

www.sec.gov